|
NO2694640T3
(cg-RX-API-DMAC7.html)
*
|
2011-04-15 |
2018-03-17 |
|
|
|
WO2013009701A2
(en)
|
2011-07-08 |
2013-01-17 |
The University Of North Carolina At Chapel Hill |
Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
|
|
CA2902594C
(en)
*
|
2013-03-14 |
2023-01-10 |
Curadev Pharma Private Ltd. |
Inhibitors of the kynurenine pathway
|
|
SG10201707545XA
(en)
|
2013-03-14 |
2017-10-30 |
Newlink Genetics Corp |
Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
CN103382187B
(zh)
*
|
2013-08-06 |
2015-06-03 |
信实生物医药（上海）有限公司 |
一种3-氯-7(5)-溴苯并异恶唑的合成方法
|
|
TWI736517B
(zh)
|
2013-12-24 |
2021-08-21 |
美商必治妥美雅史谷比公司 |
作為抗癌劑之新穎三環化合物
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
MY181896A
(en)
|
2014-06-06 |
2021-01-12 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
|
JP6680766B2
(ja)
*
|
2014-09-05 |
2020-04-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
癌治療のためのインドール−アミン−２，３−ジオキシゲナーゼ（ｉｄｏ）拮抗薬としてのシクロヘキシル−エチル置換ジアザ及びトリアザ三環化合物
|
|
GB201417369D0
(en)
*
|
2014-10-01 |
2014-11-12 |
Redx Pharma Ltd |
Compounds
|
|
GB201418300D0
(en)
*
|
2014-10-15 |
2014-11-26 |
Redx Pharma Ltd |
Compounds
|
|
HUE054526T2
(hu)
|
2014-10-29 |
2021-09-28 |
Bicyclerd Ltd |
MT1-MMP-ra specifikus biciklusos peptid ligandumok
|
|
US10100129B2
(en)
|
2014-11-21 |
2018-10-16 |
Bristol-Myers Squibb Company |
Antibodies against CD73 and uses thereof
|
|
US10525035B2
(en)
|
2014-12-18 |
2020-01-07 |
Lankenau Institute For Medical Research |
Methods and compositions for the treatment of retinopathy and other ocular diseases
|
|
AR103232A1
(es)
|
2014-12-22 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTAGONISTAS DE TGFbR
|
|
EP3237448A1
(en)
|
2014-12-23 |
2017-11-01 |
Bristol-Myers Squibb Company |
Antibodies to tigit
|
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
|
CN105884828A
(zh)
*
|
2015-02-16 |
2016-08-24 |
上海迪诺医药科技有限公司 |
多环化合物、其药物组合物及应用
|
|
US9884868B2
(en)
|
2015-03-02 |
2018-02-06 |
Rigel Pharmaceuticals, Inc. |
TGF-beta inhibitors
|
|
KR20170134980A
(ko)
|
2015-04-03 |
2017-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료를 위한 인돌아민-2,3-디옥시게나제의 억제제
|
|
TW201642897A
(zh)
|
2015-04-08 |
2016-12-16 |
Ｆ 星生物科技有限公司 |
Ｈｅｒ２結合劑治療
|
|
JP6806342B2
(ja)
*
|
2015-04-10 |
2021-01-06 |
ベイジーン リミテッド |
インドールアミンとしての新規５又は８−置換イミダゾ［１，５−ａ］ピリジン類、及び／又はトリプトファン２，３−ジオキシゲナーゼ
|
|
JP2018511647A
(ja)
*
|
2015-04-12 |
2018-04-26 |
ハンジョウ イノゲート ファーマ カンパニー リミテッドＨａｎｇｚｈｏｕ Ｉｎｎｏｇａｔｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． |
Ｉｄｏ阻害剤とｔｄｏ阻害剤としての複素環化合物
|
|
TWI725966B
(zh)
|
2015-04-13 |
2021-05-01 |
戊瑞治療有限公司 |
癌症組合療法
|
|
WO2016169421A1
(zh)
*
|
2015-04-21 |
2016-10-27 |
江苏恒瑞医药股份有限公司 |
咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
|
|
WO2016183114A1
(en)
|
2015-05-11 |
2016-11-17 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
US10174024B2
(en)
|
2015-05-12 |
2019-01-08 |
Bristol-Myers Squibb Company |
5H-pyrido[3,2-B]indole compounds as anticancer agents
|
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
HUE061253T2
(hu)
|
2015-05-29 |
2023-06-28 |
Bristol Myers Squibb Co |
Antitestek OX40 ellen és azok felhasználásai
|
|
GB2548542A
(en)
*
|
2015-06-16 |
2017-09-27 |
Redx Pharma Plc |
Compounds
|
|
CN106256830B
(zh)
*
|
2015-06-18 |
2019-03-08 |
成都海创药业有限公司 |
一种氘代的ido抑制剂及其制备方法和用途
|
|
MX2017016502A
(es)
|
2015-06-29 |
2018-03-12 |
Univ Rockefeller |
Anticuerpos contra cd40 con actividad agonista mejorada.
|
|
CN105037371A
(zh)
*
|
2015-06-30 |
2015-11-11 |
西华大学 |
一种氘代的吲哚胺-2,3-双加氧酶抑制剂
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
US10682390B2
(en)
|
2015-07-16 |
2020-06-16 |
Biokine Therapeutics Ltd. |
Compositions and methods for treating cancer
|
|
PE20180928A1
(es)
|
2015-07-24 |
2018-06-08 |
Newlink Genetics Corp |
Sales y profarmacos de 1-metil-d-triptofano
|
|
KR20180034548A
(ko)
|
2015-07-28 |
2018-04-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Tgf 베타 수용체 길항제
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
JP2018525415A
(ja)
|
2015-08-25 |
2018-09-06 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｔｇｆベータ受容体アンタゴニスト
|
|
CN106478634B
(zh)
*
|
2015-09-01 |
2020-05-22 |
尚华医药科技(江西)有限公司 |
稠合咪唑化合物、其制备方法、药物组合物和用途
|
|
WO2017075341A1
(en)
*
|
2015-10-29 |
2017-05-04 |
Scifluor Life Sciences, Inc. |
Fused imidazole derivatives as ido/tdo inhibitors
|
|
PE20181300A1
(es)
|
2015-11-02 |
2018-08-09 |
Five Prime Therapeutics Inc |
Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer
|
|
WO2017080934A1
(en)
*
|
2015-11-09 |
2017-05-18 |
F. Hoffmann-La Roche Ag |
Screening assay to identify id01 and/or tdo modulators
|
|
JP6983776B2
(ja)
|
2015-11-19 |
2021-12-17 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
|
|
CN116327924A
(zh)
|
2015-11-23 |
2023-06-27 |
戊瑞治疗有限公司 |
用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
|
|
US10450318B2
(en)
|
2015-12-15 |
2019-10-22 |
Bristol-Myers Squibb Company |
CXCR4 receptor antagonists
|
|
WO2017107979A1
(en)
|
2015-12-24 |
2017-06-29 |
Genentech, Inc. |
Tdo2 inhibitors
|
|
CN107056785B
(zh)
*
|
2016-01-02 |
2021-06-22 |
杭州英创医药科技有限公司 |
作为ido和tdo抑制剂的杂环化合物
|
|
AU2017215424A1
(en)
|
2016-02-02 |
2018-08-09 |
Emcure Pharmaceuticals Limited |
Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
|
|
TWI743088B
(zh)
*
|
2016-02-19 |
2021-10-21 |
大陸商正大天晴藥業集團股份有限公司 |
作爲免疫調節劑的三並環化合物
|
|
EP3416725A1
(en)
|
2016-02-19 |
2018-12-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of obesity
|
|
CN108884104B
(zh)
*
|
2016-02-19 |
2021-01-15 |
正大天晴药业集团股份有限公司 |
作为免疫调节剂的三并环化合物
|
|
WO2017149469A1
(en)
|
2016-03-03 |
2017-09-08 |
Emcure Pharmaceuticals Limited |
Heterocyclic compounds useful as ido and/or tdo modulators
|
|
KR20220033522A
(ko)
|
2016-03-04 |
2022-03-16 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd73 항체와의 조합 요법
|
|
SG11201808821WA
(en)
|
2016-04-18 |
2018-11-29 |
Celldex Therapeutics Inc |
Agonistic antibodies that bind human cd40 and uses thereof
|
|
CN105732643A
(zh)
*
|
2016-04-18 |
2016-07-06 |
苏州大学 |
一种偶联物、其制备方法及在制备ido酶抑制剂和非甾体抗炎药物中的应用
|
|
CN107312005B
(zh)
*
|
2016-04-27 |
2021-12-17 |
上海翰森生物医药科技有限公司 |
具有ido/tdo抑制活性的稠合咪唑衍生物及其制备方法和应用
|
|
CN109311816A
(zh)
|
2016-05-04 |
2019-02-05 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
CN109415320A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
KR20190003687A
(ko)
|
2016-05-04 |
2019-01-09 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
|
CN109414420A
(zh)
|
2016-05-04 |
2019-03-01 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
CN109348714A
(zh)
|
2016-05-04 |
2019-02-15 |
百时美施贵宝公司 |
吲哚胺2,3-双加氧酶的抑制剂及其使用方法
|
|
EP3455218A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
EP4491236A3
(en)
|
2016-05-10 |
2025-04-02 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
CN105902542A
(zh)
*
|
2016-05-16 |
2016-08-31 |
张阳 |
一种偶联物在制备治疗心血管疾病药物中的应用
|
|
CN107383012B
(zh)
*
|
2016-05-16 |
2021-09-28 |
鲁南制药集团股份有限公司 |
含二环的咪唑醇衍生物
|
|
WO2017198159A1
(zh)
*
|
2016-05-16 |
2017-11-23 |
鲁南制药集团股份有限公司 |
含桥环的咪唑衍生物
|
|
CN107556316B
(zh)
*
|
2016-06-30 |
2021-11-12 |
鲁南制药集团股份有限公司 |
含桥环的咪唑衍生物
|
|
CN106957318B
(zh)
*
|
2016-05-19 |
2019-12-10 |
中国科学院上海有机化学研究所 |
稠合多环吲哚啉化合物、其制备方法、药物组合物及应用
|
|
JP7090034B2
(ja)
|
2016-05-20 |
2022-06-23 |
ザ ユニバーシティ オブ シカゴ |
化学療法、標的療法、光線力学療法、免疫療法及びそれらの任意の組み合わせのためのナノ粒子
|
|
AR108586A1
(es)
*
|
2016-06-10 |
2018-09-05 |
Lilly Co Eli |
Compuestos de 2,3-dihidro-1h-indol
|
|
CN107488179B
(zh)
*
|
2016-06-11 |
2024-06-07 |
鲁南制药集团股份有限公司 |
含桥环的咪唑醇衍生物
|
|
CN107556315B
(zh)
*
|
2016-06-30 |
2021-08-31 |
鲁南制药集团股份有限公司 |
含四元环的咪唑衍生物
|
|
EP4512829A3
(en)
|
2016-07-14 |
2025-06-11 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
|
US20190292179A1
(en)
|
2016-07-21 |
2019-09-26 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
|
CN107663159A
(zh)
*
|
2016-07-29 |
2018-02-06 |
上海迪诺医药科技有限公司 |
多环化合物、其药物组合物及应用
|
|
WO2018028491A1
(zh)
*
|
2016-08-09 |
2018-02-15 |
苏州国匡医药科技有限公司 |
吲哚胺2，3-双加氧酶抑制剂及其在药学中的用途
|
|
JP2019528300A
(ja)
|
2016-08-26 |
2019-10-10 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法
|
|
CN107383024B
(zh)
*
|
2016-09-12 |
2018-06-08 |
广州必贝特医药技术有限公司 |
含咪唑稠合三环类化合物及其应用
|
|
TW201815766A
(zh)
|
2016-09-22 |
2018-05-01 |
美商普雷辛肯公司 |
用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
|
|
WO2018054365A1
(en)
|
2016-09-24 |
2018-03-29 |
Beigene, Ltd. |
NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
|
|
MX2019004181A
(es)
|
2016-10-13 |
2019-10-30 |
Juno Therapeutics Inc |
Métodos y composiciones de inmunoterapia que implican moduladores de la ruta metabólica de triptófano.
|
|
TW201815793A
(zh)
*
|
2016-10-21 |
2018-05-01 |
江蘇恆瑞醫藥股份有限公司 |
一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
|
|
CN108778332B
(zh)
*
|
2016-10-21 |
2019-10-18 |
苏州盛迪亚生物医药有限公司 |
Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
|
|
EP3535243B1
(en)
|
2016-11-04 |
2021-12-15 |
Auckland Uniservices Limited |
Substituted 9h-xanthen-9-one, 9h-thioxanthen-9-one and acridin-9(10h)-one derivatives and related compounds csf-1r inhibitors for the treatment of cancer
|
|
CN106474468B
(zh)
*
|
2016-11-23 |
2020-03-27 |
中国医学科学院医学生物学研究所 |
一种复合佐剂、含该复合佐剂的疫苗及疫苗的制备方法
|
|
WO2018106579A1
(en)
*
|
2016-12-06 |
2018-06-14 |
Albert Einstein College Of Medicine, Inc. |
Drug targeting of human indoleamine 2,3-dioxygenase
|
|
WO2018113624A1
(zh)
*
|
2016-12-20 |
2018-06-28 |
深圳微芯生物科技有限责任公司 |
具有吲哚胺2,3-双加氧酶抑制活性的稠合咪唑化合物
|
|
RS61996B1
(sr)
|
2016-12-22 |
2021-07-30 |
Calithera Biosciences Inc |
Kompozicije i postupci za inhibiranje aktivnosti arginaze
|
|
CN108239091B
(zh)
*
|
2016-12-26 |
2021-08-13 |
中国医学科学院药物研究所 |
1-环己基-2-(5H-咪唑[5,1-a]异吲哚)乙基-1-酮的拆分
|
|
US10961239B2
(en)
|
2017-01-05 |
2021-03-30 |
Bristol-Myers Squibb Company |
TGF beta receptor antagonists
|
|
CA3047002A1
(en)
|
2017-01-17 |
2018-07-26 |
Board Of Regents, The University Of Texas System |
Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
|
|
WO2018175954A1
(en)
|
2017-03-23 |
2018-09-27 |
F. Hoffmann-La Roche Ag |
Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
|
|
WO2018183608A1
(en)
|
2017-03-31 |
2018-10-04 |
Five Prime Therapeutics, Inc. |
Combination therapy for cancer using anti-gitr antibodies
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
AU2018256459B2
(en)
|
2017-04-21 |
2023-12-07 |
Ikena Oncology, Inc. |
Indole AHR inhibitors and uses thereof
|
|
EA201992586A1
(ru)
|
2017-04-28 |
2020-03-03 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения с помощью полипептидов внеклеточного домена cd80
|
|
US11066392B2
(en)
|
2017-05-12 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN107176956B
(zh)
*
|
2017-05-31 |
2019-11-12 |
成都海博锐药业有限公司 |
一种ido抑制剂化合物、药用组合物、用途
|
|
EP3641762A4
(en)
|
2017-06-20 |
2021-03-10 |
C4 Therapeutics, Inc. |
N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
|
|
US11827639B2
(en)
|
2017-06-28 |
2023-11-28 |
Genentech, Inc. |
TDO2 and IDO1 inhibitors
|
|
WO2019005559A1
(en)
|
2017-06-28 |
2019-01-03 |
Genentech, Inc. |
INHIBITORS OF TDO2 AND IDO1
|
|
AU2018294314B2
(en)
|
2017-06-30 |
2024-09-19 |
Bristol-Myers Squibb Company |
Amorphous and crystalline forms of IDO inhibitors
|
|
ES2932354T3
(es)
|
2017-07-28 |
2023-01-18 |
Bristol Myers Squibb Co |
Dinucleótidos cíclicos como agentes anticáncer
|
|
JP7364552B2
(ja)
|
2017-08-02 |
2023-10-18 |
ザ ユニバーシティ オブ シカゴ |
Ｘ線誘起光線力学療法、放射線療法、放射線力学療法、化学療法、免疫療法、及びそれらの任意の組み合わせのための、ナノスケール金属有機層及び金属有機ナノプレート
|
|
US11261214B2
(en)
|
2017-08-04 |
2022-03-01 |
Bicycletx Limited |
Bicyclic peptide ligand specific for CD137
|
|
TW201910336A
(zh)
*
|
2017-08-08 |
2019-03-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
一種咪唑并異吲哚類衍生物的製備方法
|
|
CN109384791B
(zh)
*
|
2017-08-09 |
2020-09-11 |
江苏恒瑞医药股份有限公司 |
一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
|
|
TW201920202A
(zh)
|
2017-08-17 |
2019-06-01 |
瑞士商愛杜西亞製藥有限公司 |
吲哚胺2,3-二氧酶及/或色胺酸2,3-二氧酶的抑制劑
|
|
BR112020003116A2
(pt)
|
2017-08-17 |
2020-08-04 |
Ikena Oncology, Inc. |
inibidores de ahr e usos dos mesmos
|
|
EP3670518A4
(en)
|
2017-08-18 |
2021-01-06 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
TRICYCLIC COMPOUND CRYSTALS
|
|
AU2018319538B9
(en)
*
|
2017-08-22 |
2021-05-27 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
KR102651946B1
(ko)
|
2017-08-31 |
2024-03-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
KR102812783B1
(ko)
|
2017-08-31 |
2025-05-26 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
CN111051328B
(zh)
|
2017-08-31 |
2023-11-03 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
|
CN107501272B
(zh)
*
|
2017-09-05 |
2020-03-31 |
中国药科大学 |
咪唑并异吲哚类ido1抑制剂、其制备方法及应用
|
|
EP4176876A1
(en)
|
2017-09-14 |
2023-05-10 |
Lankenau Institute for Medical Research |
Methods and compositions for the treatment of cancer
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
US11623932B2
(en)
|
2017-09-22 |
2023-04-11 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
US11203592B2
(en)
|
2017-10-09 |
2021-12-21 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2019074822A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
|
KR102885797B1
(ko)
|
2017-10-10 |
2025-11-12 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
EP3694552A1
(en)
|
2017-10-10 |
2020-08-19 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
|
US11427610B2
(en)
|
2017-10-16 |
2022-08-30 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
US12209079B2
(en)
|
2017-10-19 |
2025-01-28 |
General Incorporated Association Pharma Valley Project Supporting Organization |
IDO/TDO inhibitor
|
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
|
WO2019090198A1
(en)
|
2017-11-06 |
2019-05-09 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
US11472788B2
(en)
|
2017-11-25 |
2022-10-18 |
Beigene, Ltd. |
Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019133747A1
(en)
|
2017-12-27 |
2019-07-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
CN120192415A
(zh)
|
2018-01-12 |
2025-06-24 |
百时美施贵宝公司 |
抗tim3抗体及其用途
|
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
CA3087807A1
(en)
|
2018-01-15 |
2019-07-18 |
Idorsia Pharmaceuticals Ltd |
Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
|
|
CN111247119B
(zh)
*
|
2018-01-19 |
2023-02-03 |
四川科伦博泰生物医药股份有限公司 |
脒类和胍类衍生物、其制备方法及其在医药上的应用
|
|
MX2020007799A
(es)
|
2018-01-29 |
2020-09-18 |
Merck Patent Gmbh |
Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
|
|
KR20200115620A
(ko)
|
2018-01-29 |
2020-10-07 |
메르크 파텐트 게엠베하 |
Gcn2 억제제 및 이의 용도
|
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
|
US10875894B2
(en)
|
2018-02-23 |
2020-12-29 |
Bicycletx Limited |
Multimeric bicyclic peptide ligands
|
|
KR20200130362A
(ko)
|
2018-03-08 |
2020-11-18 |
브리스톨-마이어스 스큅 컴퍼니 |
항암제로서의 시클릭 디뉴클레오티드
|
|
US11149011B2
(en)
|
2018-03-20 |
2021-10-19 |
Plexxikon Inc. |
Compounds and methods for IDO and TDO modulation, and indications therefor
|
|
JP7510879B2
(ja)
|
2018-03-21 |
2024-07-04 |
ファイヴ プライム セラピューティクス インク |
酸性ｐＨでＶＩＳＴＡに結合する抗体
|
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
|
BR112020020826A2
(pt)
|
2018-04-12 |
2021-01-19 |
Bristol-Myers Squibb Company |
Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
|
|
WO2019204257A1
(en)
|
2018-04-16 |
2019-10-24 |
Arrys Therapeutics, Inc. |
Ep4 inhibitors and use thereof
|
|
US12037323B2
(en)
|
2018-05-03 |
2024-07-16 |
Bristol-Myers Squibb Company |
Uracil derivatives as Mer-AXL inhibitors
|
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
|
AU2019291794B2
(en)
|
2018-06-27 |
2022-06-16 |
Bristol-Myers Squibb Company |
Substituted naphthyridinone compounds useful as T cell activators
|
|
HUE062412T2
(hu)
|
2018-06-27 |
2023-10-28 |
Bristol Myers Squibb Co |
Naftiridinon vegyületek mint T-sejt aktivátorok
|
|
US12454520B2
(en)
|
2018-07-06 |
2025-10-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3817748A4
(en)
|
2018-07-06 |
2022-08-24 |
Kymera Therapeutics, Inc. |
TRICYCLIC CRBN LIGANDS AND USES THEREOF
|
|
SG11202100096XA
(en)
|
2018-07-09 |
2021-02-25 |
Five Prime Therapeutics Inc |
Antibodies binding to ilt4
|
|
KR20210031722A
(ko)
|
2018-07-11 |
2021-03-22 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
|
EP3823604A4
(en)
|
2018-07-17 |
2022-03-16 |
Board of Regents, The University of Texas System |
COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE
|
|
US12059420B2
(en)
|
2018-07-23 |
2024-08-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
WO2020023356A1
(en)
|
2018-07-23 |
2020-01-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
KR102833434B1
(ko)
|
2018-09-27 |
2025-07-15 |
쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. |
인돌아민-2,3-디옥시게나아제 억제 활성을 갖는 퀴놀린 유도체
|
|
WO2020076969A2
(en)
|
2018-10-10 |
2020-04-16 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
|
SG11202104969RA
(en)
|
2018-11-16 |
2021-06-29 |
Bristol Myers Squibb Co |
Anti-nkg2a antibodies and uses thereof
|
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
GB201820295D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for MT1-MMP
|
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
|
WO2020132561A1
(en)
|
2018-12-20 |
2020-06-25 |
C4 Therapeutics, Inc. |
Targeted protein degradation
|
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
|
EP3897849A1
(en)
|
2018-12-21 |
2021-10-27 |
BicycleTx Limited |
Bicyclic peptide ligands specific for pd-l1
|
|
CA3133155A1
(en)
|
2019-03-19 |
2020-09-24 |
Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron |
Combination therapy for the treatment for cancer
|
|
US20220184222A1
(en)
|
2019-04-02 |
2022-06-16 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
|
US11485750B1
(en)
|
2019-04-05 |
2022-11-01 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
|
WO2020231766A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
WO2020231713A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
SG11202113154YA
(en)
|
2019-05-31 |
2021-12-30 |
Ikena Oncology Inc |
Tead inhibitors and uses thereof
|
|
CA3146406A1
(en)
|
2019-07-11 |
2021-01-14 |
Idorsia Pharmaceuticals Ltd |
Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
|
|
WO2021026179A1
(en)
|
2019-08-06 |
2021-02-11 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
|
BR112022004451A2
(pt)
|
2019-09-13 |
2022-06-21 |
Nimbus Saturn Inc |
Antagonistas de hpk1 e usos dos mesmos
|
|
JP7650867B2
(ja)
|
2019-09-19 |
2025-03-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
酸性ｐＨでＶＩＳＴＡと結合する抗体
|
|
KR20220103753A
(ko)
|
2019-11-19 |
2022-07-22 |
브리스톨-마이어스 스큅 컴퍼니 |
헬리오스 단백질의 억제제로서 유용한 화합물
|
|
CA3159071A1
(en)
|
2019-11-26 |
2021-06-03 |
Tamar I. ROSENBAUM |
Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
|
|
EP4065582B1
(en)
|
2019-11-26 |
2025-02-19 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
|
CN111333653A
(zh)
*
|
2019-12-16 |
2020-06-26 |
山东大学 |
一种icd诱导剂-ido抑制剂缀合物及制备方法与应用
|
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
BR112022012222A2
(pt)
|
2019-12-23 |
2022-09-13 |
Bristol Myers Squibb Co |
Derivados de piperazina substituídos úteis como ativadores de células t
|
|
KR20220119454A
(ko)
|
2019-12-23 |
2022-08-29 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 퀴나졸리닐 화합물
|
|
EP4081524B1
(en)
|
2019-12-23 |
2025-01-29 |
Bristol-Myers Squibb Company |
Substituted heteroaryl compounds useful as t cell activators
|
|
KR20220151160A
(ko)
|
2019-12-23 |
2022-11-14 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Smarca 분해제 및 이의 용도
|
|
KR20220119456A
(ko)
|
2019-12-23 |
2022-08-29 |
브리스톨-마이어스 스큅 컴퍼니 |
T 세포 활성화제로서 유용한 치환된 퀴놀리노닐 피페라진 화합물
|
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
|
AU2021206618A1
(en)
|
2020-01-06 |
2022-08-18 |
Hifibio, Inc. |
Anti-TNFR2 antibody and uses thereof
|
|
IL294466A
(en)
|
2020-01-07 |
2022-09-01 |
Hifibio Hk Ltd |
Anti-galectin-9 antibody and uses thereof
|
|
AR121047A1
(es)
|
2020-01-15 |
2022-04-13 |
Blueprint Medicines Corp |
Inhibidores de map4k1
|
|
EP4114529A1
(en)
|
2020-03-03 |
2023-01-11 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
WO2021183428A1
(en)
|
2020-03-09 |
2021-09-16 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
|
WO2021188948A1
(en)
|
2020-03-19 |
2021-09-23 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
|
EP4132971A1
(en)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinity matured anti-lap antibodies and uses thereof
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
EP4161521A4
(en)
|
2020-06-03 |
2024-07-10 |
Kymera Therapeutics, Inc. |
DEUTERED IRAQ DEGRADERS AND USES THEREOF
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
CN111803635B
(zh)
*
|
2020-06-17 |
2023-03-14 |
中国医学科学院基础医学研究所 |
小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
|
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
|
US11839659B2
(en)
|
2020-07-02 |
2023-12-12 |
Northwestern University |
Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
|
|
TW202220653A
(zh)
|
2020-07-30 |
2022-06-01 |
美商凱麥拉醫療公司 |
治療突變淋巴瘤之方法
|
|
US20230303695A1
(en)
|
2020-08-10 |
2023-09-28 |
Tengfei XIAO |
Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
|
|
JP2023538906A
(ja)
|
2020-08-17 |
2023-09-12 |
バイシクルティーエクス・リミテッド |
ネクチン－４に特異的な二環コンジュゲート及びその使用
|
|
AU2021360782A1
(en)
|
2020-10-14 |
2023-06-08 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
AU2021400725A1
(en)
|
2020-12-16 |
2023-08-03 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
JP2024503300A
(ja)
|
2020-12-30 |
2024-01-25 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
US20250186539A2
(en)
|
2021-01-11 |
2025-06-12 |
Bicycletx Limited |
Methods for treating cancer
|
|
US20230113202A1
(en)
|
2021-02-02 |
2023-04-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
EP4288430A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
US20240109899A1
(en)
|
2021-02-04 |
2024-04-04 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
|
CA3210553A1
(en)
|
2021-02-12 |
2022-08-18 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
JP2024506909A
(ja)
|
2021-02-12 |
2024-02-15 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
AU2022220043A1
(en)
|
2021-02-15 |
2023-08-31 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
|
US11773103B2
(en)
|
2021-02-15 |
2023-10-03 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
KR20230152715A
(ko)
|
2021-03-05 |
2023-11-03 |
유니버시타트 바셀 |
Ebv 관련 질환 또는 질병의 치료용 조성물
|
|
EP4052705A1
(en)
|
2021-03-05 |
2022-09-07 |
Universität Basel Vizerektorat Forschung |
Compositions for the treatment of ebv associated diseases or conditions
|
|
EP4301756A4
(en)
|
2021-03-05 |
2025-02-26 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND THEIR USES
|
|
EP4305041A1
(en)
|
2021-03-08 |
2024-01-17 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
|
JP2024513011A
(ja)
|
2021-03-29 |
2024-03-21 |
ニンバス サターン， インコーポレイテッド |
Ｈｐｋ１アンタゴニスト及びその使用
|
|
US20240376224A1
(en)
|
2021-04-02 |
2024-11-14 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
|
EP4320125A1
(en)
|
2021-04-05 |
2024-02-14 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
|
|
WO2022216644A1
(en)
|
2021-04-06 |
2022-10-13 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds
|
|
WO2022217276A1
(en)
|
2021-04-09 |
2022-10-13 |
Nimbus Clio, Inc. |
Cbl-b modulators and uses thereof
|
|
JP2024514879A
(ja)
|
2021-04-16 |
2024-04-03 |
イケナ オンコロジー， インコーポレイテッド |
Ｍｅｋ阻害剤及びその使用
|
|
IL308314A
(en)
|
2021-05-07 |
2024-01-01 |
Kymera Therapeutics Inc |
CDK2 compounds and their uses
|
|
MX2024000751A
(es)
|
2021-07-14 |
2024-03-25 |
Blueprint Medicines Corp |
Compuestos heterociclicos como inhibidores de map4k1.
|
|
US20240336630A1
(en)
|
2021-07-15 |
2024-10-10 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
|
EP4392421A1
(en)
|
2021-08-25 |
2024-07-03 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
|
CA3229560A1
(en)
|
2021-08-25 |
2023-03-02 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
|
US12091411B2
(en)
|
2022-01-31 |
2024-09-17 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
JP2025503312A
(ja)
|
2022-02-01 |
2025-01-30 |
アルビナス・オペレーションズ・インコーポレイテッド |
Ｄｇｋ標的化化合物およびその使用
|
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
|
CA3252253A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
|
IL318575A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
|
|
TW202416972A
(zh)
|
2022-08-02 |
2024-05-01 |
英商利米那生物科技有限公司 |
經取代之吡啶酮gpr84拮抗劑及其用途
|
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
|
JP2025528134A
(ja)
|
2022-08-08 |
2025-08-26 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔ細胞活性化剤として有用な置換テトラゾリル化合物
|
|
EP4568963A1
(en)
|
2022-08-09 |
2025-06-18 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
|
KR20250048020A
(ko)
|
2022-08-11 |
2025-04-07 |
에프. 호프만-라 로슈 아게 |
바이시클릭 테트라히드로티아제핀 유도체
|
|
PE20251399A1
(es)
|
2022-08-11 |
2025-05-22 |
Hoffmann La Roche |
Derivados de tetrahidrotiazepina biciclicos
|
|
AR130169A1
(es)
|
2022-08-11 |
2024-11-13 |
Hoffmann La Roche |
Derivados de tetrahidrotiazepina bicíclicos
|
|
JP2025526726A
(ja)
|
2022-08-11 |
2025-08-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
二環式テトラヒドロアゼピン誘導体
|
|
AR131141A1
(es)
|
2022-11-22 |
2025-02-19 |
Pic Therapeutics Inc |
Inhibidores de eif4e y usos de los mismos
|
|
CN116143726B
(zh)
*
|
2022-12-02 |
2024-09-06 |
广州市联瑞制药有限公司 |
一种环磷腺苷杂质的制备方法
|
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
|
CN121057732A
(zh)
|
2023-05-08 |
2025-12-02 |
百时美施贵宝公司 |
经取代的苯基噁唑酮化合物
|
|
AU2024269298A1
(en)
|
2023-05-10 |
2025-11-27 |
Blueprint Medicines Corporation |
Gsk3a inhibitors and methods of use thereof
|
|
WO2024249540A1
(en)
|
2023-05-31 |
2024-12-05 |
Bristol-Myers Squibb Company |
Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
|
|
WO2024254227A1
(en)
|
2023-06-07 |
2024-12-12 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
|
IL321486A
(en)
|
2023-06-23 |
2025-08-01 |
Kymera Therapeutics Inc |
Iraqi joints and their uses
|
|
WO2024263853A1
(en)
|
2023-06-23 |
2024-12-26 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
|
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
|
WO2025064197A1
(en)
|
2023-09-02 |
2025-03-27 |
Bristol-Myers Squibb Company |
Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
|
|
AR133696A1
(es)
|
2023-09-02 |
2025-10-22 |
Bristol Myers Squibb Co |
Compuestos de fenil oxooxazolil piperidinadiona sustituida
|
|
KR20250068738A
(ko)
|
2023-09-13 |
2025-05-16 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 옥소이소인돌리닐 피페리딘-2,6-디온 화합물
|
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096488A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096539A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096489A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096505A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
|
WO2025226767A1
(en)
|
2024-04-24 |
2025-10-30 |
Bristol-Myers Squibb Company |
Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
|
|
CN119707950A
(zh)
*
|
2024-12-24 |
2025-03-28 |
无锡市南京大学锡山应用生物技术研究所 |
一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用
|